| Primary |
| Multiple Myeloma |
40.0% |
| Retinoblastoma |
6.0% |
| Malignant Melanoma |
5.4% |
| Amyloidosis |
4.4% |
| Bone Marrow Conditioning Regimen |
4.3% |
| Prophylaxis |
4.2% |
| Non-hodgkin's Lymphoma |
4.1% |
| Product Used For Unknown Indication |
4.1% |
| Stem Cell Transplant |
4.0% |
| Hypertension |
3.2% |
| Thrombosis Prophylaxis |
3.1% |
| Acute Myeloid Leukaemia |
2.8% |
| Retinoblastoma Unilateral |
2.5% |
| Constipation |
2.1% |
| Bone Marrow Transplant |
1.9% |
| Prophylaxis Against Transplant Rejection |
1.9% |
| Neuroblastoma |
1.7% |
| Neutropenia |
1.6% |
| Malignant Melanoma Stage Iii |
1.5% |
| Drug Use For Unknown Indication |
1.3% |
|
| Toxicity To Various Agents |
11.5% |
| Vitreous Haemorrhage |
9.4% |
| Pyrexia |
9.0% |
| Pneumonia |
8.1% |
| Death |
5.1% |
| Neutropenia |
4.7% |
| Renal Failure |
4.7% |
| Cellulitis |
4.3% |
| Retinoblastoma |
4.3% |
| Thrombocytopenia |
4.3% |
| Venoocclusive Disease |
4.3% |
| Mucosal Inflammation |
3.8% |
| Sepsis |
3.8% |
| Extraocular Muscle Disorder |
3.4% |
| Eye Excision |
3.4% |
| Febrile Neutropenia |
3.4% |
| Retinal Detachment |
3.4% |
| Acute Myeloid Leukaemia |
3.0% |
| Graft Versus Host Disease |
3.0% |
| Syncope |
3.0% |
|
| Secondary |
| Multiple Myeloma |
48.9% |
| Prophylaxis |
6.3% |
| Product Used For Unknown Indication |
6.3% |
| Stem Cell Transplant |
6.2% |
| Drug Use For Unknown Indication |
4.3% |
| Prophylaxis Against Graft Versus Host Disease |
3.8% |
| Hypertension |
3.7% |
| Constipation |
2.8% |
| Bone Marrow Conditioning Regimen |
2.2% |
| Thrombosis Prophylaxis |
2.0% |
| Mantle Cell Lymphoma |
1.9% |
| Acute Lymphocytic Leukaemia |
1.6% |
| Nausea |
1.4% |
| Acute Myeloid Leukaemia |
1.4% |
| Diffuse Large B-cell Lymphoma |
1.4% |
| Pain |
1.3% |
| Medulloblastoma |
1.2% |
| Hodgkin's Disease |
1.2% |
| Infection Prophylaxis |
1.2% |
| Non-hodgkin's Lymphoma |
1.2% |
|
| Myelodysplastic Syndrome |
16.4% |
| Death |
11.6% |
| Acute Myeloid Leukaemia |
9.8% |
| Sepsis |
8.2% |
| General Physical Health Deterioration |
5.5% |
| Pyrexia |
5.0% |
| Acute Graft Versus Host Disease |
4.1% |
| Septic Shock |
4.1% |
| Thrombocytopenia |
3.9% |
| Pneumonia |
3.4% |
| Renal Failure |
3.4% |
| Graft Versus Host Disease |
3.2% |
| Prostate Cancer |
3.2% |
| Venoocclusive Disease |
3.2% |
| Acute Leukaemia |
3.0% |
| Mucosal Inflammation |
2.7% |
| Multiple Myeloma |
2.5% |
| Chronic Graft Versus Host Disease |
2.3% |
| Cataract |
2.1% |
| Gastric Cancer |
2.1% |
|
| Concomitant |
| Multiple Myeloma |
22.0% |
| Product Used For Unknown Indication |
17.1% |
| Bone Marrow Conditioning Regimen |
10.8% |
| Prophylaxis Against Graft Versus Host Disease |
9.1% |
| Infection Prophylaxis |
8.8% |
| Prophylaxis |
7.0% |
| Premedication |
3.9% |
| Antifungal Prophylaxis |
3.1% |
| Stem Cell Transplant |
2.4% |
| Acute Lymphocytic Leukaemia |
2.1% |
| Hypertension |
2.1% |
| Antiviral Prophylaxis |
1.6% |
| Drug Use For Unknown Indication |
1.5% |
| Pain |
1.5% |
| Acute Myeloid Leukaemia |
1.5% |
| Antibiotic Prophylaxis |
1.4% |
| Prophylaxis Of Nausea And Vomiting |
1.2% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.1% |
| Rheumatoid Arthritis |
0.9% |
| Acute Graft Versus Host Disease |
0.7% |
|
| Weight Decreased |
14.0% |
| Thrombocytopenia |
8.0% |
| Vomiting |
8.0% |
| Tooth Extraction |
6.5% |
| Acute Graft Versus Host Disease |
6.2% |
| Multiple Myeloma |
5.7% |
| Drug Ineffective |
5.4% |
| Death |
4.4% |
| Pyrexia |
4.4% |
| Osteonecrosis Of Jaw |
4.1% |
| Pneumonia |
3.9% |
| Weight Increased |
3.9% |
| Diarrhoea |
3.6% |
| Wound Drainage |
3.6% |
| Neutropenia |
3.4% |
| Sepsis |
3.4% |
| Thrombotic Microangiopathy |
3.4% |
| Acute Myeloid Leukaemia |
2.8% |
| Pancytopenia |
2.8% |
| Cytomegalovirus Test Positive |
2.6% |
|
